Non Hodgkin Lymphoma Clinical Trial
Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
This protocol is designed as a long-term follow-up study of participants who will receive genetically modified autologous CAR-T cells as part of clinical trial at the Medical College of Wisconsin/ Froedtert Hospital-- Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055).
The objective is to follow participants receiving cluster of differentiation (CD) 20 / cluster of differentiation (CD) 19 lentiviral modified CAR-T cells (CAR-20/19-T cells) from years 2 to 15 post-treatment for persistence of CAR-T cells, development of secondary malignancies, or other medical complications.
All participants who enrolled in the Phase 1 CAR-20/19-T cell study at Froedtert & the Medical College of Wisconsin.
There are no exclusion criteria for this study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.